BINEX Valuation

Is A053030 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A053030 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A053030 (₩16260) is trading below our estimate of fair value (₩189568.48)

Significantly Below Fair Value: A053030 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A053030?

Key metric: As A053030 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A053030. This is calculated by dividing A053030's market cap by their current revenue.
What is A053030's PS Ratio?
PS Ratio	4x
Sales	₩128.30b
Market Cap	₩517.84b

A053030 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.5x
Enterprise Value/EBITDA	-38.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A053030's PS Ratio compare to its peers?

The above table shows the PS ratio for A053030 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.2x
A170900 Dong-A ST	0.8x	6.2%	₩554.0b
A019170 Shinpoong PharmaceuticalLtd	2.6x	n/a	₩577.5b
A001060 JW Pharmaceutical	0.8x	10.3%	₩591.4b
A249420 Ildong Pharmaceutical	0.6x	7.8%	₩339.7b
A053030 BINEX	4x	28.9%	₩517.8b

Price-To-Sales vs Peers: A053030 is expensive based on its Price-To-Sales Ratio (4x) compared to the peer average (1.2x).

Price to Sales Ratio vs Industry

How does A053030's PS Ratio compare vs other companies in the KR Pharmaceuticals Industry?

3 Companies	Price / Sales	Estimated Growth	Market Cap
A009290 Kwang Dong Pharmaceutical	0.1x	n/a	US$158.67m
A002620 Jeil Pharma Holdings	0.2x	n/a	US$92.36m
A000230 Ildong Holdings	0.1x	n/a	US$57.08m

No more companies available in this PS range

3 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: A053030 is expensive based on its Price-To-Sales Ratio (4x) compared to the KR Pharmaceuticals industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is A053030's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A053030 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	4x
Fair PS Ratio	4.6x

Price-To-Sales vs Fair Ratio: A053030 is good value based on its Price-To-Sales Ratio (4x) compared to the estimated Fair Price-To-Sales Ratio (4.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩271,000.00

-1.8%

76.5%

J2KBIO

₩52.5b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,180.00

-4.8%

n/a

Ildong Pharmaceutical

₩339.7b

Develops, manufactures, and sells pharmaceutical products in South Korea.

A249420

₩12,160.00

0.08%

-29.3%